| Scott A Milsteen, MD | |
|
4999 Louise Dr, Ste 105, Mechanicsburg, PA 17055-6907 | |
| (717) 766-1127 | |
| (717) 766-5518 |
| Full Name | Scott A Milsteen |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 38 Years |
| Location | 4999 Louise Dr, Mechanicsburg, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013907484 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD043118E (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pinnacle Health Hospitals | Harrisburg, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North American Partners In Anesthesia, Pennsylvania , Llc | 7517960834 | 368 |
News Archive
MedAssurant Inc., a leading provider of data-driven healthcare solutions, today announced that it has entered into a definitive agreement with the National Committee for Quality Assurance, the organization that maintains the Healthcare Effectiveness Data and Information Set (HEDIS ®)—the most widely used performance measurement tool in healthcare and a core component of the Medicare Star Rating system—to support the development of new measures of healthcare quality that NCQA is developing under a contract it has with the Centers for Medicare & Medicaid Services.
ZIOPHARM Oncology, Inc. today announced the initiation of the pivotal Phase III clinical trial for palifosfamide in patients with front-line metastatic soft tissue sarcoma. The study, called PICASSO 3, is an international, randomized, double-blinded, placebo-controlled trial designed to enroll approximately 424 patients with metastatic soft tissue sarcoma who have never been treated with chemotherapy for metastatic disease.
A pilot programme for the 'Ambition: Health' scheme is targeting areas of high unemployment that also have NHS skills shortages. It will also offer in-work support to encourage career progression.
The most comprehensive analysis yet of the genetic imbalances at the heart of childhood brain tumors known as high-grade gliomas (HGGs) identified a cancer gene that is unusually active in some tumors and is now the focus of a St. Jude Children's Research Hospital clinical trial.
In a mouse model of multiple sclerosis (MS), researchers funded by the National Institutes of Health have developed innovative technology to selectively inhibit the part of the immune system responsible for attacking myelin-the insulating material that encases nerve fibers and facilitates electrical communication between brain cells.
› Verified 8 days ago
| Entity Name | Riverside Anesthesia Associates, Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205827359 PECOS PAC ID: 6305758038 Enrollment ID: O20031103000137 |
News Archive
MedAssurant Inc., a leading provider of data-driven healthcare solutions, today announced that it has entered into a definitive agreement with the National Committee for Quality Assurance, the organization that maintains the Healthcare Effectiveness Data and Information Set (HEDIS ®)—the most widely used performance measurement tool in healthcare and a core component of the Medicare Star Rating system—to support the development of new measures of healthcare quality that NCQA is developing under a contract it has with the Centers for Medicare & Medicaid Services.
ZIOPHARM Oncology, Inc. today announced the initiation of the pivotal Phase III clinical trial for palifosfamide in patients with front-line metastatic soft tissue sarcoma. The study, called PICASSO 3, is an international, randomized, double-blinded, placebo-controlled trial designed to enroll approximately 424 patients with metastatic soft tissue sarcoma who have never been treated with chemotherapy for metastatic disease.
A pilot programme for the 'Ambition: Health' scheme is targeting areas of high unemployment that also have NHS skills shortages. It will also offer in-work support to encourage career progression.
The most comprehensive analysis yet of the genetic imbalances at the heart of childhood brain tumors known as high-grade gliomas (HGGs) identified a cancer gene that is unusually active in some tumors and is now the focus of a St. Jude Children's Research Hospital clinical trial.
In a mouse model of multiple sclerosis (MS), researchers funded by the National Institutes of Health have developed innovative technology to selectively inhibit the part of the immune system responsible for attacking myelin-the insulating material that encases nerve fibers and facilitates electrical communication between brain cells.
› Verified 8 days ago
| Entity Name | North American Partners In Anesthesia, Pennsylvania , Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639137854 PECOS PAC ID: 7517960834 Enrollment ID: O20060807000040 |
News Archive
MedAssurant Inc., a leading provider of data-driven healthcare solutions, today announced that it has entered into a definitive agreement with the National Committee for Quality Assurance, the organization that maintains the Healthcare Effectiveness Data and Information Set (HEDIS ®)—the most widely used performance measurement tool in healthcare and a core component of the Medicare Star Rating system—to support the development of new measures of healthcare quality that NCQA is developing under a contract it has with the Centers for Medicare & Medicaid Services.
ZIOPHARM Oncology, Inc. today announced the initiation of the pivotal Phase III clinical trial for palifosfamide in patients with front-line metastatic soft tissue sarcoma. The study, called PICASSO 3, is an international, randomized, double-blinded, placebo-controlled trial designed to enroll approximately 424 patients with metastatic soft tissue sarcoma who have never been treated with chemotherapy for metastatic disease.
A pilot programme for the 'Ambition: Health' scheme is targeting areas of high unemployment that also have NHS skills shortages. It will also offer in-work support to encourage career progression.
The most comprehensive analysis yet of the genetic imbalances at the heart of childhood brain tumors known as high-grade gliomas (HGGs) identified a cancer gene that is unusually active in some tumors and is now the focus of a St. Jude Children's Research Hospital clinical trial.
In a mouse model of multiple sclerosis (MS), researchers funded by the National Institutes of Health have developed innovative technology to selectively inhibit the part of the immune system responsible for attacking myelin-the insulating material that encases nerve fibers and facilitates electrical communication between brain cells.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott A Milsteen, MD 4999 Louise Dr, Ste 105, Mechanicsburg, PA 17055-6907 Ph: (717) 766-1127 | Scott A Milsteen, MD 4999 Louise Dr, Ste 105, Mechanicsburg, PA 17055-6907 Ph: (717) 766-1127 |
News Archive
MedAssurant Inc., a leading provider of data-driven healthcare solutions, today announced that it has entered into a definitive agreement with the National Committee for Quality Assurance, the organization that maintains the Healthcare Effectiveness Data and Information Set (HEDIS ®)—the most widely used performance measurement tool in healthcare and a core component of the Medicare Star Rating system—to support the development of new measures of healthcare quality that NCQA is developing under a contract it has with the Centers for Medicare & Medicaid Services.
ZIOPHARM Oncology, Inc. today announced the initiation of the pivotal Phase III clinical trial for palifosfamide in patients with front-line metastatic soft tissue sarcoma. The study, called PICASSO 3, is an international, randomized, double-blinded, placebo-controlled trial designed to enroll approximately 424 patients with metastatic soft tissue sarcoma who have never been treated with chemotherapy for metastatic disease.
A pilot programme for the 'Ambition: Health' scheme is targeting areas of high unemployment that also have NHS skills shortages. It will also offer in-work support to encourage career progression.
The most comprehensive analysis yet of the genetic imbalances at the heart of childhood brain tumors known as high-grade gliomas (HGGs) identified a cancer gene that is unusually active in some tumors and is now the focus of a St. Jude Children's Research Hospital clinical trial.
In a mouse model of multiple sclerosis (MS), researchers funded by the National Institutes of Health have developed innovative technology to selectively inhibit the part of the immune system responsible for attacking myelin-the insulating material that encases nerve fibers and facilitates electrical communication between brain cells.
› Verified 8 days ago
Arthur Cronin, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4999 Louise Dr, Ste 105, Mechanicsburg, PA 17055 Phone: 717-766-1127 Fax: 717-766-5518 | |
Joseph F Waldner, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4999 Louise Dr, Ste 105, Mechanicsburg, PA 17055 Phone: 717-766-1127 Fax: 717-766-5518 | |
Glenn C Keyser, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4999 Louise Dr, Ste 105, Mechanicsburg, PA 17055 Phone: 717-766-1127 Fax: 717-766-5518 | |
Keith K Maliniak, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 4999 Louise Dr, Suite 105, Mechanicsburg, PA 17055 Phone: 717-766-1127 Fax: 717-766-5518 | |
Nicholas A Deantonio, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4999 Louise Dr, Suite 105, Mechanicsburg, PA 17055 Phone: 717-766-1127 Fax: 717-766-5518 | |
Joseph F Answine, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4999 Louise Dr, Suite 105, Mechanicsburg, PA 17055 Phone: 717-766-1127 Fax: 717-766-5518 |